Abstract
Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.
| Original language | English |
|---|---|
| Pages (from-to) | 2498-2504 |
| Number of pages | 7 |
| Journal | Retina |
| Volume | 35 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- Central serous chorioretinopathy
- Photodynamic therapy
- Verteporfin
ASJC Scopus subject areas
- Ophthalmology
Cite this
Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. / Shiode, Yusuke; Morizane, Yuki; Kimura, Shuhei; Hosokawa, Mio; Kawata, Tetsuhiro; Doi, Shinichiro; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio.
In: Retina, Vol. 35, No. 12, 2015, p. 2498-2504.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of halving the irradiation time or the verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy
AU - Shiode, Yusuke
AU - Morizane, Yuki
AU - Kimura, Shuhei
AU - Hosokawa, Mio
AU - Kawata, Tetsuhiro
AU - Doi, Shinichiro
AU - Hosogi, Mika
AU - Fujiwara, Atsushi
AU - Shiraga, Fumio
PY - 2015
Y1 - 2015
N2 - Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.
AB - Purpose: To compare the efficacy and safety of photodynamic therapy using reduced irradiation time or reduced verteporfin dose for chronic central serous chorioretinopathy. Methods: Between April 2011 and December 2013, 45 eyes with chronic central serous chorioretinopathy (43 consecutive patients) were treated with photodynamic therapy, using either half the irradiation time (18 eyes) or half the verteporfin dose (27 eyes). Outcome measures at follow-up, over at least 3 months, were complete resolution of serous retinal detachment, best-corrected visual acuity, and central retinal thickness. Results: After 3 months, serous retinal detachment had completely resolved in 88.8% of eyes in both treatment groups, which were therefore not significantly different. The logarithm of the minimal angle of resolution best-corrected visual acuity (Snellen equivalent) improved from 0.245 (20/35) to 0.130 (20/27) (P , 0.05, paired t-test) in the reduced time group and from 0.283 (20/38) to 0.138 (20/27) (P , 0.05) in the reduced verteporfin group. Final best-corrected visual acuities in the 2 groups were not significantly different. Central retinal thicknesses dropped from 337.0 mm to 146.6 mm (P , 0.05) in the reduced time group and from 343.5 mm to 166.9 mm (P , 0.05) in the reduced verteporfin group. No ocular or systemic side effects were observed. Conclusion: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.
KW - Central serous chorioretinopathy
KW - Photodynamic therapy
KW - Verteporfin
UR - http://www.scopus.com/inward/record.url?scp=84948468144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948468144&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000000621
DO - 10.1097/IAE.0000000000000621
M3 - Article
C2 - 26035398
AN - SCOPUS:84948468144
VL - 35
SP - 2498
EP - 2504
JO - Retina
JF - Retina
SN - 0275-004X
IS - 12
ER -